Show simple item record

dc.contributor.authorPrieto-Torres, Lucia
dc.contributor.authorRodriguez-Pinilla, Socorro M.
dc.contributor.authorOnaindia, Arantza
dc.contributor.authorAra, Mariano
dc.contributor.authorRequena Caballero, Luis 
dc.contributor.authorPiris, Miguel
dc.contributor.otherUAM. Departamento de Anatomía Patológicaes_ES
dc.contributor.otherUAM. Departamento de Medicinaes_ES
dc.contributor.otherInstituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD)es_ES
dc.date.accessioned2019-10-25T13:26:40Z
dc.date.available2019-10-25T13:26:40Z
dc.date.issued2019-01-31
dc.identifier.citationHaematologica 104.2 (2019): 226-235es_ES
dc.identifier.issn0390-6078 (print)es_ES
dc.identifier.issn1592-8721 (online)es_ES
dc.identifier.urihttp://hdl.handle.net/10486/688989
dc.description.abstractPrimary cutaneous CD30-positive T-cell lymphoproliferative disorders are the second most common subgroup of cutaneous T-cell lymphomas. They include two clinically different entities with some overlapping features and borderline cases: lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. Molecular studies of primary cutaneous anaplastic large cell lymphoma reveal an increasing level of heterogeneity that is associated with histological and immunophenotypic features of the cases and their response to specific therapies. Here, we review the most significant genetic, epigenetic and molecular alterations described to date in primary cutaneous CD30-positive T-cell lymphoproliferative disorders, and their potential as therapeutic targets.en_US
dc.description.sponsorshipThis work was supported by grants from the Instituto de Salud Carlos III (ISCIII) of the Spanish Ministry of Economy and Competence (MINECO, RTICC ISCIII and CIBERONC) (SAF2013-47416-R, RD06/0020/0107-RD012/0036/0060 and Plan Nacional I+D+I: PI17/2172, PI16/01294 and PIE15/0081), AECC and the Madrid Autonomous Community.en_US
dc.format.extent10 pag.es_ES
dc.format.mimetypeapplication/pdfen
dc.language.isoengen
dc.publisherFerrata Storti Foundationes_ES
dc.relation.ispartofHaematologicaes_ES
dc.rights© 2019 Ferrata Storti Foundationes_ES
dc.subject.otherCD30-positiveen_US
dc.subject.otherT-cellen_US
dc.subject.otherLymphoproliferativeen_US
dc.subject.otherCutaneousen_US
dc.subject.otherMolecular alterationsen_US
dc.titleCD30-positive primary cutaneous lymphoproliferative disorders: Molecular alterations and targeted therapiesen_US
dc.typearticleen
dc.subject.ecienciaMedicinaes_ES
dc.relation.publisherversionhttps://doi.org/10.3324/haematol.2018.197152es_ES
dc.identifier.doi10.3324/haematol.2018.197152es_ES
dc.identifier.publicationfirstpage226es_ES
dc.identifier.publicationissue2es_ES
dc.identifier.publicationlastpage235es_ES
dc.identifier.publicationvolume104es_ES
dc.relation.projectIDGobierno de España. SAF2013-47416-Res_ES
dc.relation.projectIDGobierno de España. RD06/0020/0107es_ES
dc.relation.projectIDGobierno de España. RD012/0036/0060es_ES
dc.relation.projectIDGobierno de España. PI17/2172es_ES
dc.relation.projectIDGobierno de España. PI16/01294es_ES
dc.relation.projectIDGobierno de España. PIE15/0081es_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionen
dc.rights.ccReconocimiento – NoComerciales_ES
dc.rights.accessRightsopenAccessen
dc.authorUAMRodríguez Pinilla, Socorro María (262752)
dc.authorUAMRequena Caballero, Luis (258697)
dc.facultadUAMFacultad de Medicina
dc.institutoUAMInstituto de Investigación Sanitaria Fundación Jiménez Díaz (ISS-FJD)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record